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Work from this laboratory has previously demonstrated  that  the function of the 
complement receptor of the resident mouse peritoneal macrophage can be converted 
in  vitro from mediating only particle binding  to promoting both the binding and 
ingestion of complement-coated erythrocytes (1, 2).  Enhanced complement receptor 
function is  imparted  to macrophages  by a  low  molecular weight  lymphokine, the 
generation and elaboration of which require a  unique series of cellular interactions 
(1).  Macrophages  must  first  phagocytize IgG-containing immune complexes; these 
cells  thereby acquire  the  ability to trigger,  by a  contact-dependent  mechanism,  T 
lymphocytes to elaborate the product that augments the complement receptor func- 
tion of freshly explanted macrophages. The effect of the lymphokine upon  macro- 
phages' phagocytic capability is selective and specific for the complement receptor, 
for lymphokine-treated maerophages do not indiscriminately interiorize all particles 
bound to their plasma membranes and do not more avidly, more efficiently, or more 
rapidly phagocytize IgG-coated particles via their Fc receptors (2). 
All  of the  cellular  and  molecular  eomponents--macrophages,  T  lymphocytes, 
antigen, antibody, immune complexes, and complement components--necessary for 
both the generation of the lymphokine and the expression of its activity are present at 
sites of immunologically mediated inflammation. We previously suggested that  this 
lymphokine may be important in a variety of infectious, inflammatory, and neoplastic 
disorders  and  proposed  a  model  by which  the appropriate cellular and  molecular 
interactions might occur in vivo (1). Briefly, microorganisms and tumor cells become 
coated with both IgG and C3b in the immune host. These offenders also shed antigens 
that become bound by host antibody. Macrophages present at sites ofimmunologically 
mediated inflammation are, therefore, exposed to large quantities of immune com- 
plexes composed of IgG and  either microbial  antigens  or neoantigens from tumor 
cells. We proposed that ingestion of these complexes might block or saturate the cells' 
Fc receptors so that macrophages would be unable to phagocytize via these receptors 
the offenders they were invited to destroy. In their normal physiologic state, macro- 
phages could bind the microbe or tumor cell via their C3b receptors but could not 
ingest  it  and  would  probably  release  it  when  C3b  inactivator  cleaved  C3b;  the 
offender would be unharmed after such an encounter (3,  4).  However, ingestion of 
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immune  complexes  would  permit  macrophages  to  interact  with  T  lymphocytes, 
thereby  triggering  the  lymphocytes  to  elaborate  the  lymphokine  which  enhances 
macrophages'  complement  receptor  function.  Macrophages  would  then  be  able  to 
ingest and to destroy the invaders via their complement receptors. 
For  our  model  to  have  pathophysiologic  relevance,  several  conditions  must  be 
satisfied.  First,  ingestion of soluble  immune complexes must result  in severe impair- 
ment of macrophage Fc receptor function. Second, ingestion of these complexes must 
not impair the macrophages' interaction with particles by other means, especially via 
their  complement  receptors.  Third,  macrophages  that  have  ingested  immune com- 
plexes must be able to respond to the lymphokine and to phagocytize complement- 
coated particles.  Results of experiments reported in this paper satisfy these conditions 
and provide strong evidence in support of the proposed model. 
Materials  and Methods 
Reagents and Media.  Glutaraidehyde, 50% aqueous solution (Fisher Scientific Co., Pittsburgh, 
Pa.); sheep erythrocytes (E) 1 (Animal Blood Center, Syracuse, N. Y.); fetal bovine serum (FBS) 
(Grand Island Biological Co., Grand Island, N. Y.);  trypsin  (lot  T8253, twice recrystallized; 
Sigma Chemical Co., St. Louis, Mo.); ovomucoid trypsin inhibitor (Worthington Biochemical 
Corp., Freehold, N. J.); and Medium 199 (Microbiological Associates,  Walkersville, Md.) were 
obtained from the manufacturers indicated. FBS was decomplemented by heating at 56°C for 
30 min before use.  Lyophilized human serum albumin (HSA; recrystallized five times; Sigma 
Chemical Co.) was reconstituted in phosphate-buffered saline (PBS)  at a concentration of 20 
mg/ml.  Lyophilized rabbit  gamma globulin  (N.  L. Cappel  Laboratories Inc., Cochranville, 
Pa.) was reconstituted in PBS at a concentration of 10 mg/ml; a portion of the reconsitituted 
material was aggregated by heating at 63°C for 45 min (5). A 0.1-ml aliquot containing 0.5 mg 
of aggregated IgG was incubated  with 0.1  ml of fresh  mouse serum  for  10 rain  at  37°C  to 
prepare complement-treated IgG aggregates. 
Antibody  Preparations.  Rabbit anti-sheep E IgG and rabbit anti-sheep E IgM were obtained 
from Cordis Laboratories Inc. (Miami, Fla.).  Rabbit anti-ox E IgG was a gift from Dr. E. Pearl, 
University of Alabama in  Birmingham, Birmingham, Ala.  Rabbit  anti-HSA antiserum  was 
prepared by repeatedly immunizing a rabbit with HSA; it was heat decomplemented (56°C, 
30 min) before use. Rhodamine-labeled HSA, rhodamine-labeled rabbit IgG, and rhodamine- 
labeled Fab fragments of rabbit IgG were gifts from Dr. S. Jackson, University of Alabama in 
Birmingham, Birmingham, Ala.; portions of the IgG and Fab preparations were aggregated by 
heating at 63°C for 45 min. 
Immunologically  Coated Erythrocytes.  E, E coated with  anti-E IgM (E[IgM]), E(IgM) coated 
with the first four complement components (E[IgM]C), E coated with anti-E IgG (E[IgG]), and 
E(IgG)  coated  with  the  first  four  complement  components  (E[IgG]C)  were  prepared  as 
previously described (4, 6). Some E(IgG) were prepared using smaller quantities of anti-E IgG. 
E(IgM)C-IgG were prepared by incubating E(IgM)C with  1/~l/ml of anti-E IgG for 15 rain at 
37°C. Ox erythrocytes (ox E) coated with anti-ox E IgG (oxE[IgG]) were prepared as previously 
described (1). 
Preparation of Soluble Immune Complexes.  1 ml ofanti-HSA antiserum was incubated with  I0 
mg of HSA, some aliquots of which were rhodamine-labeled  for 1 h  at  37°C. Although the 
exact antigen-antibody ratio cannot be determined, the mixture contained an excess of antigen, 
the estimated molar ratio being at least  10:1, assuming 25% of the IgG in the antiserum was 
specific for HSA. No precipitates of a size sufficient to cloud the solution were formed. Sham 
immune complexes were prepared exactly as HSA-anti-HSA complexes, but using nonimmune 
rabbit serum in place of immune serum. 
I Abbreviations used in this paper:  AI, attachment  index; E, sheep erythrocytes; E(IgG), E coated with 
anti-E IgG; E(IgG)C, E(IgG) coated with the first four complement components; E(IgM), E coated with 
anti-E IgM; E(IgM)C, E(IgM) coated with the first four complement components; E(IgM)C-IgG, E(IgM)C 
coated with anti-E IgG; FBS, fetal bovine serum; HSA, human serum albumin; ox E, ox erythrocytes; 
oxE(IgG), ox E coated with anti-ox E IgG; PBS, phosphate-buffered saline; PI, phagocytic index. FRANK  M.  GRIFFIN, JR.  907 
Complement-treated immune complexes were prepared by incubating 0.1 ml of HSA-anti- 
HSA complexes containing 0.17  mg of HSA with 0.1  ml of fresh  mouse serum for  10 rain at 
37°C. 
Animals and Cells.  20- to 30-g female mice (strain CD-1) were obtained from Charles River 
Breeding Laboratories, Inc., Wilmington, Mass.  They served as sources  of peritoneal macro- 
phages and thymocytes, which were cultivated and used as previously described (1). 
Fluorescence Microscopy.  Macrophage  cultures that  had  been  incubated with  rhodamine- 
labeled  material  were  fixed  with  glutaraldehyde  and  examined  with  a  Leitz  Orthoplan 
fluorescence microscope (E. Leitz, Inc., Rockleigh, N. J.) equipped with a C5 100 W/2 mercury 
vapor lamp (Philips Electronic Instruments, Inc., Mahwah, N. J.), a  Ploem epi-illumination 
system, dichroic mirrors, and filters selective for rhodamine (7). 
Preparation of Supernates Containing the Lymphokine That Augments Macrophage Complement Receptor 
Function.  Supernatant media were prepared as described previously (1). Briefly,  monolayers 
containing 1 ×  10  s mouse peritoneal macrophages were overlaid with fresh  medium without 
FBS; either 0.2  ml of 0.5% oxE(IgG) or HSA-anti-HSA complexes containing 1 mg of HSA 
were added to each monolayer and incubation continued for 4 h at 37°C. Cultures were then 
washed and noningested erythrocytes lysed with NH4CI where appropriate. 5 ×  10  n thymocytes 
in medium were added to each dish and incubation continued for 24 h at 37°C. Supernatant 
medium from each culture was harvested, centrifuged at 750 g for  10 rain to remove cells and 
cellular debris, and assayed for its effect upon macrophage complement receptor function, as 
described below. There was no substantial difference in lymphokine activity between supernates 
prepared using oxE(IgG) and those prepared using HSA-anti-HSA complexes as the material 
fed to macrophages. Results are therefore presented without regard to which was used. 
Assessment of Lymphokine Activity.  Lymphokine activity was assessed in two ways.  The first, 
which will be referred to as the preincubation assay, was performed as previously described (I). 
Freshly established macrophage monolayers were covered with experimental supernates and 
incubated at  37°C  for 48  h;  supernates were  removed and monolayers covered with  fresh 
medium. The complement receptor function of these macrophages was assessed by adding 0.2 
ml of 0.5% E(IgM)C, incubating the cultures for 30 min at 37°C, and determining the fate of 
the E(IgM)C by phase contrast microscopy. 
The second method, which will be referred to as the direct assay, was performed as previously 
described (2). 48-h explanted resident mouse peritoneal macrophages, which had been main- 
tained in medium-20% FBS, were washed and overlaid with supernates. E(IgM)C were added 
to cultures simultaneously with supernates, incubation continued for 30 min at 37°C, and the 
fate of E(IgM)C was determined microscopically. 
The effect of the lymphokine upon Fc receptor-mediated and nonimmunologically  mediated 
phagocytosis was assessed exactly as described above, using E(IgG) and zymosan, respectively, 
in place of E(IgM)C. 
Phase Contrast Microscopy.  Cover slip cultures were fixed with glutaraldehyde and examined 
by phase contrast microscopy as previously described (1). 
Miscellaneous.  Protein concentrations were determined by the method of Lowry et al.  (8), 
using bovine serum albumin as a  standard. Cell viability was  assessed  by determining the 
ability of cells to exclude 0.4% trypan blue dye in 0.15  M  NaCI after  10 min at 25°C. Some 
macrophages were treated with trypsin as previously described (4). 
Presentation of Results.  Each  result given represents the average of at  least three separate 
determinations, each performed in duplicate. Attachment index (AI) and phagocytic index (PI) 
are the number of erythrocytes attached or ingested by t00 macrophages and were obtained by 
multiplying the percent of macrophages that had attached or ingested any erythrocytes by the 
average number of erythrocytes attached or ingested per macrophage. Each result is presented 
as mean -  SEM. 
Results 
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and to define the structure and physical state of IgG required for its uptake, the fate 
of rhodamine-labeled IgG and complexes was determined microscopically. 
Macrophages were incubated for 1 h at 37°C with either of the following:  HSA- 
anti-HSA  complexes  prepared  with  rhodamine-labeled  HSA;  sham  complexes,  a 
mixture of  rhodamine-labeled HSA and nonimmune rabbit serum; rhodamine-labeled 
rabbit  IgG; rhodamine-labeled, heat-aggregated rabbit  IgG; or rhodamine-labeled, 
heat-aggregated Fab fragments of rabbit IgG. 
Bright field microscopy revealed that macrophages that had been incubated with 
either HSA-anti-HSA complexes  or aggregated IgG contained numerous pinocytic 
vacuoles, whereas macrophages that had been incubated with any of the other three 
preparations  did  not.  These  results  suggested  that  only  immune  complexes  and 
aggregated IgG were ingested by macrophages. 
This suggestion was confirmed by fluorescence  microscopy.  97 and 83% of macro- 
phages  that  had  been  incubated  with  either  rhodamine-labeled  HSA-anti-HSA 
complexes  or rhodamine-labeled aggregated IgG, respectively,  demonstrated bright 
red  intracytoplasmic, granular  fluorescence,  whereas  only  a  small  percentage  of 
macrophages that had been incubated with any of the control preparations contained 
rhodamine-labeled material (Table I). Thus, immune complexes and aggregated IgG 
were  avidly  ingested  by  macrophages,  uptake  of IgG  required  that  it  be  either 
aggregated  or  bound  to  antigen,  and  uptake  occurred  via  the  macrophages'  Fc 
receptors. 
Effect of Ingestion  of Soluble Immune  Complexes upon Macrophages" Ability  to Ingest  IgG- 
coated Particles.  The next experiments were designed to determine whether or not 
soluble  immune complexes  and aggregates could block or saturate macrophage Fc 
receptors  so that the cell's ability to phagocytize IgG-coated particles was impaired. 
Macrophages were incubated for 1 h at 37°C with varying concentrations of either 
soluble  HSA-anti-HSA complexes  or  heat-aggregated rabbit  IgG,  which  behaves 
similarly in many respects  to immune complexes  (5, 9). Cultures were then washed 
and incubated for 30 min at 37°C with E(IgG)  that had been prepared using varying 
concentrations of anti-E IgG.  Nonaggregated IgG, anti-HSA antiserum alone, and 
sham complexes,  a  mixture containing both  HSA and  nonimmune rabbit  serum, 
served as controls. As indicated in Fig. 1, previous uptake of either immune complexes 
or aggregated IgG by macrophages impaired, in a dose-dependent manner, the cells' 
ability to ingest  E(IgG).  Macrophages that  had not  ingested complexes  efficiently 
TABLE  I 
Ingestion of Soluble Immune Complexes and Aggregated IgG by Macrophages 
Macrophages 
Macrophages incubated with:  containing 
rhodamine label 
HSA*-anti-HSA 
HSA*-nonimmune serum~ 
Nonaggregated rabbit IgG* 
Aggregated rabbit I6=13" 
Aggregated Fab fragments* of IgG 
% 
97 
6 
10 
83 
18 
* Rhodamine labeled. 
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Fla.  1.  Effect of ingestion of soluble immune complexes and aggregated rabbit ISG upon macro- 
phages' ability to ingest E(IgG). Macrophages were preincubated for 1 h at 37°C with either HSA- 
anti-HSA complexes, the HSA contents of which are indicated on the abscissa (a), or the quantities 
of aggregated lgG indicated on the abscissa (b). These macrophages were then incubated for 30 min 
at 37°C with E(IgG) prepared with 3 (C)), I  (O), 0.5 (I--I), or 0.1  (I)/.d/ml  of anti-E lgG and the 
PI (ordinate) determined. 
ingested  E(IgG)  prepared  with  1 #l/ml  or  more  anti-E  IgG  but  ingested  E(IgG) 
prepared with smaller quantities of antibody less efficiently. Inhibition of phagocytosis 
of E(IgG)  was  dependent  upon  both  the  concentration  of IgG  in  complexes  or 
aggregates and the concentration of IgG used to opsonize erythrocytes (Fig.  1). None 
of the control preparations affected the ability of macrophages to phagocytize E(IgG) 
(data not shown). 
In  all subsequent experiments,  I  prepared  E(IgG)  with  1 #l/ml  of anti-E  IgG, a 
concentration  that  yielded nearly  maximal  ingestion  of E(IgG)  by normal  macro- 
phages,  and  used 0.17  mg  (HSA concentration)  of HSA-anti-HSA and  0.5  mg of 
aggregated IgG per culture, concentrations that inhibited the uptake of these E(IgG) 
by >95%. 
Effect  of  Ingestion of  Soluble Immune Complexes upon Macrophages" Ability  to  Bind 
E(IgG).  Whereas  ingestion of aggregates and complexes strikingly  impaired  mac- 
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of their ability to bind E(IgG)  (Table II, column 1). Macrophages possess two classes 
of Fc receptors: a trypsin-sensitive receptor that recognizes mouse IgG2a and a trypsin- 
resistant  receptor that  recognizes mouse IgG1  and  IgG2b  (10).  In  addition  to their 
differences  in  immunoglobulin  subclass  recognition,  these  receptors  may  mediate 
different functions, the trypsin-sensitive receptor promoting only particle binding, the 
trypsin-resistant receptor promoting both particle binding and ingestion (11). Because 
particles coated with rabbit IgG may bind to both classes of receptor, it was possible 
that  aggregates and  immune complexes nearly completely blocked the  function of 
one class but had little or no effect on the other. 
To test this possibility, macrophages were fed aggregated IgG or HSA-anti-HSA 
complexes, washed, subjected to trypsin treatment, then incubated with E(IgG) for 30 
min at 37°C. Attachment of E(IgG) by these macrophages was markedly lower than 
attachment by companion macrophages that had not been trypsin-treated (Table II, 
lines 2 and 3). As we have previously shown (4), trypsin treatment had no effect on 
the ability of normal  macrophages to bind  E(IgG)  (Table II, line  1). These results 
indicate  that  residual  attachment  of E(IgG)  by  macrophages  that  had  ingested 
immune complexes was mediated by trypsin-sensitive Fc receptors and that nearly all 
trypsin-resistant Fc receptor activity was blocked by the ingestion of immune com- 
plexes. Because the E(IgG) bound to macrophages that  had ingested immune com- 
plexes were not phagocytized, these results also support the hypothesis that trypsin- 
sensitive Fc receptors promote binding but not ingestion of IgG-coated particles. 
Effect of Ingestion of Soluble Immune Complexes upon Macrophages" Ability to Bind and Ingest 
Particles by  Means  other than Their  Fc  Receptors.  Macrophages,  some  of which  had 
ingested either aggregated IgG or HSA-anti-HSA complexes, were incubated for 30 
min at  37°C with either zymosan, a  particle which is ingested by nonimmunologic 
means,  or E(IgM)C, a  particle whose interaction with macrophages is governed by 
the  cells'  complement  receptors.  Macrophages  that  had  previously ingested  either 
aggregated IgG or immune complexes bound E(IgM)C and phagocytized zymosan as 
effectively as nonpretreated macrophages (Table III). Even using maximum noncy- 
totoxic quantities of aggregates and complexes, I was unable to find a concentration 
that  impaired macrophages'  ability to interact with  particles by means other than 
their Fc receptors (data not shown). 
These results indicate that  the ingestion of soluble immune complexes selectively 
blocks  Fc  receptor-mediated  phagocytosis  but  does  not  alter  the  interaction  of 
macrophages with particles by other immunologic or nonimmunologic mechanisms. 
Effect  of Ingestion  of Soluble Immune Complexes upon the  Ability  of Lymphokine-treated 
Macrophages to Phagocytize Various Particles.  Some macrophage cultures were preincu- 
TABLE II 
Effect of lngestion of Soluble Immune Complexes upon Macrophages' Ability to 
Bind E(IgG) 
AI of E(IgG) by macrophages  that were  Macrophages preincubated 
with:  Nontreated  Trypsin-treated 
--  1,465 _. 12  1,470 ± 11 
HSA-anti-HSA  1,425 +_ 11  172 + 78 
Aggregated IgG  1,420 ± 6  55 ± 5 FRANK M.  GRIFFIN, JR. 
TABLE III 
Effect of lngestion of Soluble Immune Complexes upon Macrophages' Ability to 
Bind and Ingest Particles by Means Other than Their Fc Receptors 
Macrophages preincubated  AI of E(IgM)C  PI of zymosan 
with: 
--  1,078 4- 122  529 4- 16 
HSA-anti-HSA  1,063 4- 197  497 4- 28 
Aggregated IgG  1,055 4- 155  480 4- 47 
911 
TABLE IV 
Effect of Ingestion of Soluble Immune Complexes upon the Ability of Lymphokine-treated Macrophages to 
Ingest Various Particles 
PI of particle by macrophages 
Macrophages preincu-  Particle presented  Not treated  Treated with lymphokine 
bated with:  with 
lymphokine  By preincuba-  Directly 
tion 
--  E(IgM)C  5 4- 2  278 4- 59  226 4- 16 
HSA-anti-HSA  E(IgM)C  5 4- 4  236 4- l0  225 4- 26 
Aggregated lgG  E(IgM)C  4 4- 3  291 4- 25  218 4- 13 
--  E(IgG)  1,114 4- 48  I, 148 ± 43  979 ±  100 
HSA-anti-HSA  E(IgG)  20 4- 4  31 4- 6  32 ±  12 
Aggregated IgG  E(IgG)  24 4- 3  28 4- 9  27 4- 4 
--  Zymosan  529 4- 16  469 :lz 19  504:1:21 
HSA-anti-HSA  Zymosan  497 4- 28  498 4- 18  498 4- 17 
Aggregated IgG  Zymosan  480 4- 47  474 4- 18  508 ± 25 
bated  in  supernates  containing  the  lymphokine  that  imparts  to  macrophages  the 
ability to phagocytize via their complement receptors. Cultures were washed, overlaid 
with  fresh medium  containing either aggregated IgG or HSA-anti-HSA complexes, 
incubated for 1 h  at 37°C, washed, and incubated for 30 min at 37°C with E(IgM)C 
(preincubation  assay).  Other  cultures  were  incubated  for  I  h  at  37°C  with  either 
aggregated IgG or HSA-anti-HSA complexes, washed, overlaid with supernates and 
E(IgM)C simultaneously, and incubated for 30 min at 37°C (direct assay). Erythrocyte 
attachment and ingestion were scored microscopically. 
All macrophages avidly bound  E(IgM)C  (data not shown).  The results of phago- 
cytosis  assays  are  presented  in  Table  IV,  lines  1-3.  Like  normal  macrophages, 
macrophages which had been preincubated with either aggregated IgG or HSA-anti- 
HSA complexes did not  ingest E(IgM)C  (Table IV, column  1, lines  1-3), indicating 
that the ingestion of complexes does not trigger macrophages to ingest particles bound 
to  their  complement  receptors,  a  result  consistent  with  our  previous  finding  that 
triggering one type of phagocytic receptor does not trigger other receptors that have 
the potential to phagocytize (4,  12). 
Macrophages that had been treated with lymphokine-containing supernates, either 
by preincubation or at the time of assay, efficiently phagocytized E(IgM)C, with PI 
of 278  and 226, respectively (Table IV, line  1, columns 2  and  3).  Macrophages that 912  EFFECTS  OF SOLUBLE IMMUNE COMPLEXES ON PHAGOCYTOSIS 
ingested IgG aggregates or complexes either after preincubation in supernates (prein- 
cubation assay)  (Table IV, column 2, lines 2 and 3) or before exposure to supernates 
(direct assay)  (Table IV, column 3, lines 2 and 3) ingested E(IgM)C as efficiently as 
macrophages which had not ingested complexes. 
In parallel cultures, aggregate- and complex-treated macrophages ingested zymosan 
particles normally but were unable to ingest E(IgG)  (Table IV, column 1, lines 4-9). 
Supernate treatment did not enhance the ability of aggregate- or complex-treated 
macropbages to ingest E(IgG)  (Table IV, columns 2 and 3, lines 4-6), confirming our 
previous  finding that supernates do not augment Fc receptor function (2). Neither 
did supernate treatment enhance the ability ofmacrophages to ingest zymosan (Table 
IV,  columns 2  and  3,  lines  7-9),  demonstrating that  supernates  do  not  augment 
nonimmunologically mediated phagocytosis. 
These results  indicate that ingestion of immune complexes  by macrophages does 
not impair either the macrophages' ability to respond to supernates or the ability of 
supernate-treated macrophages to phagocytize via their complement receptors. 
Effect of Ingestion of Soluble Immune Complexes upon Macrophages" Ability to Ingest Particles 
Coated with Both IgG and C3b.  At sites of immunologically mediated inflammation in 
an  immune  host,  the  target  to  be  attacked  is  coated  with  both  IgG  and  C3b. 
Macrophage complement receptors  very efficiently promote binding of C3b-coated 
particles,  and the interaction of macrophage Fe receptors with particle-bound IgG is 
greatly strengthened when the particle is coated with both ligands and bound by 
both receptors  (13). Immune complexes  may therefore have been unable to block Fc 
receptors  sufficiently well to prevent phagocytosis of particles coated with both IgG 
and  C3b.  To  test  this  possibility,  I  determined  the  effect  of ingestion of soluble 
immune complexes upon the ability ofsupernate-treated and nontreated macrophages 
to interact with particles coated with both immunologic ligands. 
Macrophages were fed soluble IgG-containing complexes  or aggregates, as in the 
experiments described above.  Some cultures were treated with supernates, either by 
preincubation or during the assay culture, also as described above, and the interaction 
of the various macrophage preparations with erythrocytes coated with both IgG and 
C3b was assessed. 
Erythroeytes coated with both IgG and C3b--E(IgG)C and E(IgM)C-IgG--were 
prepared as described in Materials and Methods. Both E(IgG)C and E(IgM)C-IgG 
were  used  for two reasons.  First,  in  some circumstances, complement  fixation by 
antigen-antibody complexes results in the deposition of  complement component(s) on 
or  near  the  Fc  portion  of the  immunoglobulin  (14, 15), thereby  preventing  the 
interaction of the immunoglobulin with macrophage Fc receptors  (15). Thus, had 
macrophages failed to ingest E(IgG)C, the result might have been due to nonavaila- 
bility of the Fc portion of IgG to the cells' Fc receptors.  Second, in order for C3- and 
Fc-receptor cooperation to occur, it might be important for IgG and C3b to be in 
close  proximity on  the  particle  surface.  Thus,  had  macrophages  failed  to  ingest 
(E(IgM)C-IgG, the result  might have been due to inappropriate distribution of the 
two ligands. 
Normal macrophages avidly ingested erythrocytes coated with both ligands (Table 
V,  column  1,  lines  1 and  4).  Previous  ingestion of IgG-containing aggregates  or 
complexes  had no effect upon the ability of macrophages to bind these erythrocytes 
(data not shown)  but markedly impaired the cells' ability to ingest  them (Table V, FRANK M.  GRIFFIN, JR.  913 
TABLE  g 
Effect of lngestion of Soluble Immune Complexes upon Macrophages' Ability to Ingest Particles Coated with 
Both IgG and C3b 
Macrophage preincu- 
bated with:  Particle presented 
PI of E coated with both IgG and C3b by macro- 
phages 
Not treated 
with 
lymphokine  By preincuba- 
tion 
Treated with lymphokine 
Directly 
--  E(IgG)C  1,405 ± 27  1,335 ± 21  1,320 ± 27 
ttSA-anti-HSA  E(IgG)C  46 ± 3  320 ± 35  295 ± 43 
Aggregated IgG  E(IgG)C  27 +  10  307 ± 58  252 ± 20 
--  E(IgM)C-IgG  1,191 ± 38  1,066 + 35  1,029 ± 36 
HSA-anti-HSA  E(IgM)C-IgG  42 ±  11  402 ± 21  250 ± 30 
Aggregated IgG  E(IgM)C-IgG  62 ±  14  464 ± 77  364 zlz 30 
column  1, lines 2, 3,  5, and 6).  Supernate-treated  macrophages, on the other hand, 
were fully capable of ingesting both E(IgG)C and E(IgM)C-IgG, even after their Fc 
receptors  had  been  inhibited  with  immune  complexes  and  aggregates  (Table  V, 
columns 2 and 3, and compare with Table IV, columns 2 and 3, lines  1-3). 
These results indicate  that  immune complexes efficiently block the interaction of 
the  macrophage's Fc  receptors  with  particle-bound  IgG, even when  the  particle  is 
coated with C3b as well, and confirm our previous finding (16)  that particles coated 
with  both  IgG  and  C3b  are  phagocytized  only  via  the  Fc  receptors  of  normal 
macrophages.  They  also  demonstrate  that  the  ability  of macrophage complement 
receptors to mediate phagocytosis is critically important  to macrophages that  have 
ingested soluble immune complexes, even when the cells encounter a  particle coated 
with both IgG and C3b ligands. 
Effect  of Ingestion of Complement-treated Soluble Immune  Complexes upon Macrophages'  Fc 
and  C3  Receptor Function.  As  previously  indicated,  coating  immobilized  immune 
complexes with complement may mask the Fc portion of the IgG molecule and make 
it unavailable to macrophage Fc receptors (15). In vivo soluble immune complexes fix 
complement  (14)  and  are likely to  be coated with  complement  components.  Were 
these components  to  mask the  Fc  portion  of IgG, then  macrophages' Fc  receptors 
could  not  be engaged  by the complexes, the  cells  could  not  be triggered  to  signal 
lymphocytes to elaborate the lymphokine  (1),  and  their  Fc receptors would  not  be 
blocked. Moreover, if C3b were on the complexes and available to macrophages' C3b 
receptors, these receptors might be blocked. 
To evaluate the effect of complement treatment of soluble immune complexes upon 
the  ability  of complexes  to  be  ingested  and  to  trigger  the  macrophage  function 
necessary  for  the  generation  of supernatant  activity,  I  used  complement-treated, 
soluble  HSA-anti-HSA  complexes,  some  of which  were  rhodamine-labeled,  as  the 
material fed to macrophages in the preparation of experimental supernates.  Macro- 
phages avidly ingested these complexes, as indicated by fluorescence microscopy, and 
supernates obtained from cultures in which these macrophages had been co-cultivated 
with  thymocytes were as active as supernates  prepared using  HSA-anti-HSA com- 
plexes  that  had  not  been  incubated  with  complement  (data  not  shown).  Thus, 914  EFFECTS  OF  SOLUBLE  IMMUNE  COMPLEXES  ON  PHAGOCYTOSIS 
previous  exposure  of soluble  immune  complexes  to  complement  did  not  prevent 
macrophages from ingesting the complexes via their Fc receptors or from acquiring 
the ability to signal T  lymphocytes to elaborate the lymphokine. 
Other experiments were designed to determine the effect of exposure of macrophages 
to  complement-treated  immune  complexes upon  the cells' ability to  interact  with 
particles via their Fc and C3b receptors. Macrophages were fed either complement- 
treated HSA-anti-HSA complexes or complement-treated IgG aggregates either after 
preincubation  in  supernates  (preincubation  assay)  (Fig.  2,  open  bars)  or  before 
exposure to supernates  (direct assay)  (Fig.  2, hatched bars).  Like their counterparts 
that  had  ingested  noncomplement-treated  complexes  and  aggregates  (Table  IV), 
these macrophages were unable to ingest E(IgG), but ingested E(IgM)C as efficiently 
as macrophages that had not ingested complexes (Fig. 2). 
These results indicate that treating soluble immune complexes with large quantities 
of complement (50% serum) does not prevent the interaction  of the complexes with 
macrophage Fc receptors or the resulting Fc receptor blockade and that ingestion of 
these complexes does not block maerophages' C3b receptors or impair the cells' ability 
to respond to the lymphokine and ingest complement-coated particles. 
Discussion 
Results  of the  present  experiments  indicate  that  macrophage  Fc  receptors  are 
functionally (and perhaps physically) blocked when the cell ingests soluble immune 
complexes; that the phagocytic blockade is selective, for the ability of macrophages to 
bind and to ingest particles by other means is not impaired; and that the lymphokine 
that  augments  the complement  receptor function of normal  macrophages can  also 
augment  the  complement  receptor  function  of  macrophages  whose  Fc  receptor 
function has been severely compromised by the ingestion of immune complexes. 
In vivo experiments have previously suggested that circulating immune complexes 
can block the Fc receptors of phagocytic cells. The ability of mice to clear intravenously 
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FIG.  2.  Effect of ingestion of complement-treated soluble immune complexes upon macrophages' 
Fc  and C3  receptor  function.  Macrophages were  fed  either complement-treated  HSA-anti-HSA 
complexes or complement-treated IgG  aggregates either after  preincubation  in supernates (open 
bars)  or  before  exposure  to  supernates  (hatched  bars).  The  ceils'  ability  to  ingest  E(IgG)  and 
E(IgM)C was then assessed. Percent of Control  PI  (ordinate)  is the percent of the PI of E(IgG)  or 
E(IgM)C by macrophages that had been treated with supernates hut which had not been pretreated 
with immune complexes or aggregates. FRANK M. GRIFFIN, JR.  915 
administered HSA-anti-HSA complexes  diminishes markedly as the dose of complex 
administered is increased (17). The clearance of radiolabeled, IgG-coated erythrocytes 
from  the  circulation  occurs  much  more  slowly  in  patients  with  systemic  lupus 
erythematosus than  in  normal controls, and the degree of impairment is  directly 
related to the level of circulating immune complexes  in the patients (18). The ability 
to ingest IgG-coated particles is likewise diminished in polymorphonuclear leukocytes 
of patients with rheumatoid arthritis (19). That ingestion of soluble immune com- 
plexes in vivo is responsible  for this defect is supported by the finding that treatment 
of rheumatoid patients with penicillamine, a  drug that disrupts disulfide bonds in 
rheumatoid  factor  (20) and  thereby  diminishes  the  level  of circulating  immune 
complexes,  restores  to normal the ability of the their polymorphonuclear leukocytes 
to ingest IgG-coated latex beads (19). 
Isolated IgG and the Fc fragment of IgG can block the binding and uptake of IgG- 
coated  particles  by phagocytic cells  in  vitro  (21-27).  These  findings suggest  that 
soluble immune complexes  may also block Fc receptors,  and results  of the present 
experiments confirm that  they can.  Macrophage Fc receptor function can also  be 
blocked by plating the cells on immobilized immune complexes (15, 28-31);  here, 
even the function of  receptors on the nonbound surface of  the macrophage is impaired. 
In each of  these studies, the Fc receptor blockade was clearly mediated by immobilized 
and not by soluble complexes. In fact, Rabinovitch et al. (28) were unable to block Fc 
receptor function with soluble complexes.  The reasons  for the discrepancy between 
my findings and theirs are not known but  may be technical. For example, I  used 
complexes  containing 20  /lg  or  more  HSA,  whereas  they used  soluble  complexes 
containing only 4 #g of bovine serum albumin. Furthermore, because the degree of 
immune complex-mediated Fc receptor blockade observed in my studies was depend- 
ent upon the concentration of anti-E IgG used to opsonize the test erythrocytes (Fig. 
1), use of higher titers ofopsonizing antibody in their experiments might have masked 
the blockade. Like immobilized immune complexes  (15), soluble immune complexes 
appear to block trypsin-resistant but not trypsin-sensitive immune complexes  (Table 
IX). 
In each of the studies cited above, blockade of macrophage Fc receptor function by 
immoblized complexes  did not impair the function of other receptors  that promote 
particle  binding and  ingestion  (15, 28-31).  Likewise,  in  the  present  experiments, 
ingestion of soluble complexes  did not alter macrophages' ability to phagocytize by 
other  means.  The  mechanism  by  which  complexes  selectively  block  Fc  receptor- 
mediated  functions  is  not  known.  There  are  two  general  possibilities.  Immune 
complexes  may bind to, and result  in clearance from the plasma membrane of, the 
vast majority of Fc receptors.  Alternatively, binding or clearance of a minority of Fc 
receptors  may trigger events that lead to qualitative or quantitative alterations in the 
remaining Fc receptors. 
There are several mechanisms by which engagement or clearance of a minority of 
Fc receptors  might modify the interaction of the remaining receptors with IgG-coated 
particles.  (a)  It might alter the structure and/or binding affinity of the remaining 
receptors.  Evidence has recently been  presented  that suggests  that engagement of 
immobilized immune complexes by Fc receptors  located on only a  portion of the 
macrophage plasma membrane inhibits the function of Fc receptors  located on the 
free macrophage surface by an ATP-dependent mechanism (31). One possible expla- 916  EFFECTS  OF SOLUBLE IMMUNE COMPLEXES ON  PHAGOCYTOSIS 
nation for those findings is that a cAMP-mediated reaction, triggered by engagement 
of some of the cell's Fc receptors, resulted in a structural change in the remaining Fc 
receptors. (b) Engagement or clearance of a minority of Fc receptors might disengage 
remaining  Fc  receptors  from  a  transmembrane  communication  network  so  that 
binding of particle-bound IgG to remaining receptors fails to generate the phagocytic 
signal.  Such  an  effect might  be  mediated  by cAMP  or any of a  number of other 
intracellular  or  plasma  membrane  components.  This  hypothesis  does  not  readily 
explain how the blockade is selective for Fc receptor function and does not seem likely 
in view of my finding that nearly all trypsin-resistant Fc receptor binding activity was 
removed by immune complex treatment of macrophages (Table II).  (c) Michl et al. 
(15) have suggested that receptor aggregation may be a prerequisite for phagocytosis. 
Thus, engagement or clearance of a  minority of Fc receptors might  freeze other Fc 
receptors so that they cannot aggregate, or patch, when engaged by particle-bound 
IgG. Each of the above mechanisms is possible, especially when blockade is mediated 
by immobilized immune complexes. However, we have previously found that engage- 
ment of Fc receptors by particle-bound IgG on one portion of the macrophage plasma 
membrane does not interfere with the binding or phagocytic function of Fc receptors 
located  on  other  portions  of the  cell's  surface  (16).  Thus,  if  the  interaction  of 
macrophage Fc receptors with soluble immune complexes is similar to their interaction 
with IgG-coated particles, then none of the above mechanisms seems a  likely expla- 
nation for the blockade of Fc receptor function by soluble complexes. 
The simplest  interpretation of my results  is that  ingestion of immune complexes 
results in clearance of most phagocytosis-competent Fc receptors from the macrophage 
surface, leaving too few available to bind and to promote the ingestion of IgG-coated 
particles.  Internalization of most of the macrophage's Fc receptors would probably 
result in internalization of a large percentage of the cell's plasma membrane, raising 
the  question  of how  complement  receptors  and  other  particle-binding  sites  could 
avoid being passively interiorized as well. Tsan and Berlin (32) have shown that some 
plasma  membrane components are selectively excluded from a  phagocytic vacuole. 
Therefore, my finding that  the phagocytic blockade induced by immune complexes 
is selective for Fc receptors is not inconsistent with this simple interpretation. 
Had  treatment  of immune complexes with  complement rendered the complexes 
either incapable of binding to macrophages' Fc receptors or capable of blocking the 
cells' C3b  receptors, then the pathophysiologic relevance of the other findings pre- 
sented would  have been open  to serious question.  However, treatment  of immune 
complexes with concentrations of complement  that  approximate those likely to be 
available at inflammatory sites in vivo did not impair their ability to be recognized 
by macrophage Fc receptors, and uptake of these complexes by macrophages did not 
impair  the  ceils'  complement  receptor  function  (Fig.  2).  Therefore, the  fact  that 
complement components are likely to  be present  on soluble immune complexes in 
vivo does not appear to diminish the likelihood that selective blockade of macrophage 
Fc receptor function might  occur, and  might  be important,  in  a  variety of disease 
states. 
Soluble  immune  complexes are  present  at  most  inflammatory  sites.  My  results 
suggest that macrophages that ingest these'complexes are rendered unable to phago- 
cytize via  their Fc  receptors.  Macrophage  complement receptors are  not  normally 
phagocytic receptors (4, 6, 33). Therefore, at inflammatory sites, macrophages in their FRANK M. GRIFFIN, JR.  917 
normal physiologic state may be unable to ingest particles coated with IgG, with C3b, 
or  with  both  ligands.  Classical  delayed  hypersensitivity  mechanisms  would  not 
enhance  these  macrophages'  ability  to ingest  opsonized particles,  for lymphokines 
generated by these mechanisms do not result in augmented macrophage complement 
receptor function (1). 
However,  we  have  defined  a  series  of cellular  and  molecular  events  whereby 
macrophages may acquire the ability to phagocytize C3b-coated particles  (1).  The 
first  step  in  this  series  is  ingestion  of immune  complexes by macrophages.  Thus, 
uptake of immune complexes, whereas it paralyzes macrophages' Fc receptor function, 
at the same time initiates a sequence of cellular interactions that subsequently lead to 
the elaboration of a  lymphokine that  imparts to macrophages the ability to phago- 
cytize via their complement receptors. These macrophages may then circumvent the 
immune complex-induced phagocytic blockade and  ingest  immunologically coated 
particles via their C3b receptors. 
Summary 
The effects of ingestion of soluble immune complexes upon macrophage phagocytic 
function was studied. Ingestion of immune complexes severely impaired the macro- 
phage's ability to ingest IgG-coated particles but did not alter its ability to interact 
with particles by means other than its Fc receptors. Treatment of macrophages that 
had ingested immune complexes with supernates containing the previously described 
lymphokine  that  augments  macrophage  complement  receptor  function  failed  to 
enhance the cells' interaction with either IgG-coated erythrocytes or zymosan particles 
but markedly enhanced their ability to phagocytize via their complement receptors. 
The possible significance of these findings in immunologically mediated inflammation 
is discussed. 
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